Answers are grounded in this paper and cite their sources.
Pan-cancer analysis reveals KDM3B predicts poor prognosis and immune characteristics across cancer types, suggesting therapeutic potential.
Dysregulation of histone modifications contributes to the development of cancer. The loss of methylation on histone H3 and H4 and the loss of acetylation serve as indicators of tumors. Histone demethylase KDM3B, which contains a JmjC domain, plays an important role in tumorigenesis and development by removing H3K9me1/2 methylation. It also has a significant impact on regulating different types of cancer. KDM3B's role in prognosis and tumor formation in cancer has not been thoroughly studied. In this study, we analyzed KDM3B expression data from the TCGA database in a pan-cancer analysis. Our results show that KDM3B is highly expressed in many cancer types and is closely associated with poor prognosis. KDM3B expression is associated with immune checkpoint activities, lymphocyte infiltration, and immune landscape changes, suggesting that KDM3B could be a target for cancer therapy.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: